ArticleJournal of Korean medical science2010
A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
Article in Journal of Korean medical science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Tocilizumab for giant cell arteritis.The Cochrane database of systematic reviews · 2022Pooled it
- Tocilizumab for giant cell arteritis.The Cochrane database of systematic reviews · 2021Pooled it
- Idiopathic multicentric Castleman's disease: a systematic literature review.The Lancet. Haematology · 2016Pooled it
- Co-occurrence of Neuromyelitis Optica Spectrum Disorder and Idiopathic Multicentric Castleman Disease Successfully Treated with Tocilizumab.Internal medicine (Tokyo, Japan) · 2025Article
- Targeting IL-6 in antibody-mediated kidney transplant rejection.Clinical kidney journal · 2025Review
- The changing landscape of thyroid eye disease: current clinical advances and future outlook.Eye (London, England) · 2024Review
- Current developments in the diagnosis and treatment of giant cell arteritis.Frontiers in medicine · 2022Review
- Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021Article
- Interleukin-6: obstacles to targeting a complex cytokine in critical illness.The Lancet. Respiratory medicine · 2021Review
- The Clinical Characteristics and Outcomes of Follicular Bronchiolitis in Chinese Adult Patients.Scientific reports · 2018Article
- Tocilizumab (Actemra).Human vaccines & immunotherapeutics · 2017Review
- Interleukin-6: an emerging regulator of pathological pain.Journal of neuroinflammation · 2016Review
- Multicentric Castleman's disease: a challenging diagnosis.Pathology oncology research : POR · 2013Review
- A Case of Multicentric Castleman's Disease Presenting with Follicular Bronchiolitis.Tuberculosis and respiratory diseases · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report presents the case of a patient demonstrating multicentric Castleman's disease (MCD) with a lung lesion that was successfully treated with an anti-interleukin-6 receptor antibody, tocilizumab in combination with corticosteroid and tacrolimus. A 43-yr-old female with abnormal shadows on a chest X-ray was referred to the hospital for further examination. She was diagnosed as having MCD based on the characteristic pathology of inguinal lymph node, lung lesions, laboratory data, and undifferentiated arthritis. Corticosteroid and rituximab therapy did not fully ameliorate the symptoms; thus, the therapeutic regimen was changed to include tocilizumab, oral corticosteroid and tacrolimus. This regimen resulted in clinical remission and the dose of tocilizumab and corticosteroid could be tapered. Tocilizumab in combination with corticosteroid and tacrolimus may therefore be a beneficial treatment regimen for lung lesions associated with MCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.